Multicenter Comparative Evaluation of Six Commercial Systems and the National Committee for Clinical Laboratory Standards M27-A Broth Microdilution Method for Fluconazole Susceptibility Testing of Candida Species
Open Access
- 1 August 2002
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 40 (8) , 2953-2958
- https://doi.org/10.1128/jcm.40.8.2953-2958.2002
Abstract
Fluconazole susceptibility among 800 clinical Candida isolates (60% C. albicans ) and two control strains ( C. krusei ATCC 6258 and C. parapsilosis ATCC 22019) was tested with the NCCLS M27-A method (gold standard) and six commercial products (Candifast, disk, Etest, Fungitest, Integral System Yeasts, and Sensititre YeastOne). Results were classified as susceptible, susceptible-dose dependent, or resistant using M27-A breakpoints or, for Fungitest, Integral System Yeasts, and Candifast, as susceptible, intermediate, or resistant, according to the manufacturers' instructions. Concordance with NCCLS M27-A results was analyzed with the χ 2 test. Intra- and interlaboratory reproducibility was also evaluated. NCCLS M27-A (90.1%), Etest (93.1%), Sensititre YeastOne (93.1%), disk (96.7%), Fungitest (92.6%), Integral System Yeasts (40.6%), and Candifast (6.0%) classified the indicated percentages of C. albicans isolates as susceptible. Among non- C. albicans strains, the percentages of susceptible isolates were as follows: NCCLS M27-A, 74.0%; Etest, 83.8%; Sensititre YeastOne, 64.1%; disk, 60.6%; Fungitest, 76.6%; Integral System Yeasts, 28.3%; and Candifast, 27.4%. All methods except Candifast and Integral System Yeasts showed good agreement with NCCLS M27-A results for both C albicans and non- C. albicans isolates. Intralaboratory reproducibility was excellent for NCCLS M27-A, Etest, Sensititre YeastOne, disk, and Fungitest (88 to 91%). Similar results emerged from the interlaboratory reproducibility evaluation. Our findings indicate that some commercial methods can be useful for fluconazole susceptibility testing of clinical Candida isolates. Those characterized by a lack of medium standardization and/or objective interpretative criteria should be avoided. Particular caution is necessary when testing is being done for clinical and epidemiological purposes.Keywords
This publication has 13 references indexed in Scilit:
- Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2001
- Antifungal Susceptibility Testing: Practical Aspects and Current ChallengesClinical Microbiology Reviews, 2001
- International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance ProgramJournal of Clinical Microbiology, 2001
- Commercial systems for fluconazole susceptibility testing of yeasts: comparison with the broth microdilution methodDiagnostic Microbiology and Infectious Disease, 2000
- Fluconazole in transplant recipients: options and limitationsTransplant Infectious Disease, 2000
- A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusionDiagnostic Microbiology and Infectious Disease, 2000
- Practice Guidelines for the Treatment of CandidiasisClinical Infectious Diseases, 2000
- Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.Journal of Antimicrobial Chemotherapy, 1998
- Multisite reproducibility of MIC results by the Sensititre® YeaStone Colorimetric Antifungal Susceptibility PanelDiagnostic Microbiology and Infectious Disease, 1998
- Standardization of antifungal susceptibility testingJournal of Antimicrobial Chemotherapy, 1996